IMV Inc. (IMV) Reports Q2 Loss of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
August 11, 2021 7:05 AM EDTAppointed Andrew Hall, Chief Business Officer, as interim CEO, Jeremy Graff, PhD as Chief Scientific Officer, Stanley Frankel, MD and Jose Iglesias, MD as Clinical Advisors Strengthened financial position and extended cash runway with the completion of a $25M financing resulting in pro-forma cash and cash equivalents of $45.8 million on June 30th, 2021 Completed the DeCidE1 Phase 2 clinical study in advanced, recurrent ovarian cancer. Translational analyses confirm generation of tumor-antigen directed T cells by maveropepimut-S Initiated Phase 2B trial in... More
